PREGABALIN DETERMINATION IN POSTMORTEM SAMPLES AND TOXICOLOGICAL SIGNIFICANCE IN FORENSIC CASES
Abstract
Pregabalin (PGB) was initially developed for the treatment of epilepsy, but nowadays it is used in the management of neuropathic pain, generalized anxiety disorder, and fibromyalgia. Over the past 10 years, PGB from a prescription drug became a recreational drug. PGB was classified as having considerable “abuse liability.” Intoxications with PGB at the Institute of Forensic Medicine in Niš (South-east Serbia) in clinical and postmortem samples were noticed in recent years. The primary data consisted of the toxicological results analysis of postmortem blood and urine obtained in the authors’ laboratory during 2019. Cases of intoxications with a combination of PGB (concentrations above the therapeutic range) and other drugs and alcohol were included in this paper. Blood and urine samples were extracted using solid-phase extraction on Plexa, PCX, Agilent cartridges. Analysis method for pregabalin determination is gas chromatography with a mass spectrometer, while liquid chromatography with tandem mass spectrometry (Shimadzu), high-performance liquid chromatography with a photodiode array detector (Waters Alliance) and head-space gas chromatography with flame ionisation detector (Shimadzu) were used for other substances analysis. The abuse potential of PGB has created concerns about risks of respiratory depression and death when used with opioids or other central nervous system depressants, such as drugs found in our investigated cases. Autopsy results have shown deaths were violent and the main cause of deaths were overdose and additive, depressive effects of drugs and alcohol on CNS. Health professionals must be aware of this misuse potential, which could lead to abuse and dependence.
References
Baird CRW, Fox P, Colvin LA. Gabapentinoid abuse in order to potentiate the effect of methadone: a survey among substance misusers. Eur Addict Res 2014; 20:115-8. [CrossRef] [PubMed]
Bauer CS, Nieto-Rostro M, Rahman W. The increased trafficking of the calcium channel subunit α2δ-1 to presynaptic terminals in neuropathic pain is inhibited by the α2δ ligand pregabalin. J Neurosci 2009; 29(13):4076-88. [CrossRef] [PubMed]
Bockbrader HN, Radulovic LL, Posvar EL, Strand JC, Alvey CW, Busch JA, Randinitis EJ, et al. Clinical pharmacokinetics of pregabalin in healthy volunteers. J Clin Pharmacol 2010;50(8):941-50. [CrossRef] [PubMed]
Bonnet U, Scherbaum N. How addictive are gaba-pentin and pregabalin? A systematic review. Eur Neuropsychopharmacol 2017;27:1185-215. [CrossRef] [PubMed]
Deeb S, McKeown DA, Torrance HJ, Wylie FM, Logan BK, Scott KS. Simultaneous Analysis of 22 Antiepilep-tic Drugs in Postmortem Blood, Serum and Plasma Using LC–MS-MS with a Focus on Their Role in Forensic Cases. J Anal Toxicol 2014;38:485-94. [CrossRef] [PubMed]
Feltner DE, Crockatt JG, Dubovsky SJ, Cohn CK, Shrivastava RK, Targum SD, et al. A randomized, double-blind, placebo-controlled, fixed-dose, multi-center study of pregabalin in patients with generalized anxiety disorder. J Clin Psychopharmacol 2003;23: 240-9. [CrossRef] [PubMed]
Gahr M, Franke B, Freudenmann RW, Kölle MA, Schönfeldt-Lecuona C. Concerns about pregabalin: further experience with its potential of causing addic-tive behaviors. J Addict Med 2013;7:147-9. [CrossRef] [PubMed]
Hall TD, Shah S, Ng B, Feberwee HM, Dotchin L, Vandermost M, et al. Changes in mood, depression and suicidal ideation after commencing pregabalin for neuropathic pain. Aust Fam Physician 2014;43:705-8. [PubMed]
Jacquy J, Lossignol D, Sternon J. Pregabalin (Lyrica) and neuropathic pain syndromes. Rev Med Brux 2006; 27:445-50. [PubMed]
Lancia M, Gambelunghe A, Gili A, Bacci M, Aroni K, Gambelunghe C. Pregabalin Abuse in Combination With Other Drugs: Monitoring Among Methadone Patients. Front Psychiatry 2019;10:1022. [CrossRef] [PubMed]
Lapeyre-Mestre M, Dupui M. Drug abuse monitoring: which pharmacoepidemiological resources at the European level? Therapie 2015;70:147-65. [CrossRef] [PubMed]
Nahar LK, Murphy KG, Paterson S. Misuse and Mortality Related to Gabapentin and Pregabalin are Being Under-Estimated: A Two-Year Post-Mortem Population Study. J Anal Toxicol 2019;43(7):564-70. [CrossRef] [PubMed]
Pergolizzi JV, Taylor RA, Bisney JF, LeQuang JA, Coluzzi F, Gharibo CG. Gabapentinoid Use Disorder: Update for Clinicians. EC Anaesth 2018;4:303-17.
Robertson K. The EMCDDA annual report 2010: the state of the drugs problem in Europe. Euro Surveill 2010;15(46):19714. [CrossRef] [PubMed]
Tassone DM, Boyce E, Guyer J, Nuzum D. Pregabalin: a novel gamma-aminobutyric acid analogue in the treatment of neuropathic pain, partial-onset seizures, and anxiety disorders. Clin Ther 2007;29:26-48. [CrossRef] [PubMed]
Toth C. Pregabalin: latest safety evidence and clinical implications for the management of neuropathic pain. Ther Adv Drug Saf 2014;5:38-56. [CrossRef] [PubMed]